Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.

The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment.
Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months after treatment. Pain was evaluated using a subjective scale (from 0 to 10) before and for 8 weeks after the treatment. Blood counts were obtained before treatment and once a week for 2 months during follow-up. Dosimetry, based upon the urinary excretion of the isotope, was estimated in 41 individuals, and the resulting radiation absorbed doses were correlated with hematological data.
Reduction in pain scores of 75% to 100% was obtained in 36 patients (49%), with a decrease of 50% to 75%, 25% to 50%, and 0% to 25% in, respectively, 20 (27%), 10 (14%), and 7 (10%) patients. There was no significant relationship between the pain response and location of the primary tumor (breast or prostate cancer). Mild to moderate myelosuppression was noted in 75.3% of patients, usually with hematological recovery at 8 weeks. The mean bone marrow dose was 347 +/- 65 cGy, and only a weak correlation was found between absorbed dose and myelosuppression (Pearson coefficient = .4).
Samarium-153-EDTMP is a valuable method for metastatic bone pain palliation. A mild to moderate and transitory myelosuppression is the main toxicity observed after samarium therapy, showing a weak correlation with dosimetric measures.
AuthorsMarcelo Tatit Sapienza, Carla Rachel Ono, Maria Inês Cury Guimarães, Tomoco Watanabe, Paulo Aguirre Costa, Carlos Alberto Buchpiguel
JournalRevista do Hospital das Clinicas (Rev Hosp Clin Fac Med Sao Paulo) Vol. 59 Issue 6 Pg. 321-8 (Dec 2004) ISSN: 0041-8781 [Print] Brazil
PMID15654484 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Analgesics, Non-Narcotic
  • Organometallic Compounds
  • Organophosphorus Compounds
  • samarium Sm-153 lexidronam
  • Adult
  • Aged
  • Aged, 80 and over
  • Analgesics, Non-Narcotic (administration & dosage, adverse effects)
  • Bone Marrow (radiation effects)
  • Bone Neoplasms (complications, radiotherapy, secondary)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Organometallic Compounds (administration & dosage, adverse effects)
  • Organophosphorus Compounds (administration & dosage, adverse effects)
  • Pain (etiology, radiotherapy)
  • Pain Measurement
  • Palliative Care (methods)
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: